US Pharma MarketingRegeneron agrees to $270m extension to supply Ebola medicine in US
Regeneron Pharmaceuticals has agreed to a $270m contract extension to supply its Ebola therapy, Inmazeb, to the US Government through 2031. The arrangement builds on a partnership with BARDA within the US Department of Health and Human Services. Regeneron will supply extra doses of the three-antibody formulation to maintain national emergency stockpiles. Credit: lev radin / Shutterstock.com. Regeneron Pharmaceuticals has agreed to a nearly $270m contract extension to supply its Ebola therapy, Inmazeb, to the US Government through 2031. The arrangement builds on a partnership with the Biomedical Advanced Research and Development Authority (BARDA) established in 2020. NPVM: Ervebo Reports…
Regeneron Pharmaceuticals has agreed to a $270m contract extension to supply its Ebola therapy, Inmazeb, to the US Government through 2031.
Source: Pharmaceutical Technology